Skip to main content
Caplight Logo









Pyrotech Therapeutics

Pyrotech Therapeutics

Private
BeijingHealthcare & Life Scienceshttps://pyrotech.com/

Last Round

Early Funding

Jul 3, 2026

Total Funding Raised

$97M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Pyrotech Therapeutics is a biotechnology company that develops innovative drugs for the treatment of inflammation and tumors by targeting pyroptosis and innate immune pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryimmunotherapypyroptosissmall-molecule drugsoncolytic virusAI-assisted drug designAIDDinnate immunityclinical-stage biotechbiotech startupdrug pipelineimmunomodulatorsprecision medicinepharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pyrotech Therapeutics Comparables

Compare Pyrotech Therapeutics with similar companies based on industry and business-model similarity.

Pyrotech Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Halia Therapeutics
78%
Ventus Therapeutics
76%
Inflammasome Therapeutics
75%

Pyrotech Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJul 3, 2026
Series A ExtensionMay 24, 2024
Series AJul 10, 2023
AngelJan 1, 2021

Key People

Founding team and executive leadership

TJ Deng

CEO, Co-founder

Founding Team

Pyrotech Therapeutics Investors

Notable investors and investment history

Pyrotech Therapeutics investors
InvestorRounds
BioTrack CapitalSeries A, Angel
MSA CapitalSeries A, Angel
Frees FundSeries A, Series A Extension, Early Funding, Angel
SDIC Venture CapitalSeries A
Lilly Asia VenturesSeries A, Series A Extension, Angel
Zhongguancun Development GroupAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 3, 2026

    Raised capital led by Shanghai STVC Leading Fund.

  • May 24, 2024

    Raised Series A Extension with participation from baheal-great-health-innovation-investment-fund, Frees Fund, and Lilly Asia Ventures.

Pyrotech Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pyrotech Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pyrotech Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range12
Year Founded2020
Last FundingJul 3, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?